Literature DB >> 18790059

Lrrk2 and alpha-synuclein are co-regulated in rodent striatum.

Marie Westerlund1, Caroline Ran, Anders Borgkvist, Fredrik H Sterky, Eva Lindqvist, Karin Lundströmer, Karin Pernold, Stefan Brené, Pekka Kallunki, Gilberto Fisone, Lars Olson, Dagmar Galter.   

Abstract

LRRK2, alpha-synuclein, UCH-L1 and DJ-1 are implicated in the etiology of Parkinson's disease. We show for the first time that increase in striatal alpha-synuclein levels induce increased Lrrk2 mRNA levels while Dj-1 and Uch-L1 are unchanged. We also demonstrate that a mouse strain lacking the dopamine signaling molecule DARPP-32 has significantly reduced levels of both Lrrk2 and alpha-synuclein, while mice carrying a disabling mutation of the DARPP-32 phosphorylation site T34A or lack alpha-synuclein do not show any changes. To test if striatal dopamine depletion influences Lrrk2 or alpha-synuclein expression, we used the neurotoxin 6-hydroxydopamine in rats and MitoPark mice in which there is progressive degeneration of dopamine neurons. Because striatal Lrrk2 and alpha-synuclein levels were not changed by dopamine depletion, we conclude that Lrrk2 and alpha-synuclein mRNA levels are possibly co-regulated, but they are not influenced by striatal dopamine levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18790059     DOI: 10.1016/j.mcn.2008.08.001

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  22 in total

1.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

Review 2.  LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.

Authors:  A Raquel Esteves; Russell H Swerdlow; Sandra M Cardoso
Journal:  Exp Neurol       Date:  2014-06-04       Impact factor: 5.330

Review 3.  LRRK2 links genetic and sporadic Parkinson's disease.

Authors:  Jillian H Kluss; Adamantios Mamais; Mark R Cookson
Journal:  Biochem Soc Trans       Date:  2019-03-05       Impact factor: 5.407

Review 4.  Animal models of α-synucleinopathy for Parkinson disease drug development.

Authors:  James B Koprich; Lorraine V Kalia; Jonathan M Brotchie
Journal:  Nat Rev Neurosci       Date:  2017-07-13       Impact factor: 34.870

5.  α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells.

Authors:  Christian Hansen; Elodie Angot; Ann-Louise Bergström; Jennifer A Steiner; Laura Pieri; Gesine Paul; Tiago F Outeiro; Ronald Melki; Pekka Kallunki; Karina Fog; Jia-Yi Li; Patrik Brundin
Journal:  J Clin Invest       Date:  2011-01-18       Impact factor: 14.808

6.  Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.

Authors:  João Paulo L Daher; Olga Pletnikova; Saskia Biskup; Alessandra Musso; Sandra Gellhaar; Dagmar Galter; Juan C Troncoso; Michael K Lee; Ted M Dawson; Valina L Dawson; Darren J Moore
Journal:  Hum Mol Genet       Date:  2012-02-21       Impact factor: 6.150

7.  Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.

Authors:  Xian Lin; Loukia Parisiadou; Xing-Long Gu; Lizhen Wang; Hoon Shim; Lixin Sun; Chengsong Xie; Cai-Xia Long; Wan-Jou Yang; Jinhui Ding; Zsu Zsu Chen; Paul E Gallant; Jung-Hwa Tao-Cheng; Gay Rudow; Juan C Troncoso; Zhihua Liu; Zheng Li; Huaibin Cai
Journal:  Neuron       Date:  2009-12-24       Impact factor: 17.173

Review 8.  Are we listening to everything the PARK genes are telling us?

Authors:  Deanna L Benson; George W Huntley
Journal:  J Comp Neurol       Date:  2019-02-08       Impact factor: 3.215

9.  Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway.

Authors:  Iria Carballo-Carbajal; Susanne Weber-Endress; Giorgio Rovelli; Diane Chan; Benjamin Wolozin; Christian L Klein; Nadja Patenge; Thomas Gasser; Philipp J Kahle
Journal:  Cell Signal       Date:  2010-01-13       Impact factor: 4.315

Review 10.  LRRK2 in Parkinson's disease: in vivo models and approaches for understanding pathogenic roles.

Authors:  Zhenyu Yue
Journal:  FEBS J       Date:  2009-10-05       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.